Literature DB >> 18259690

The epidermal growth factor receptor family: biology driving targeted therapeutics.

M J Wieduwilt1, M M Moasser.   

Abstract

The epidermal growth factor family of receptor tyrosine kinases (ErbBs) plays essential roles in regulating cell proliferation, survival, differentiation and migration. The ErbB receptors carry out both redundant and restricted functions in mammalian development and in the maintenance of tissues in the adult mammal. Loss of regulation of the ErbB receptors underlies many human diseases, most notably cancer. Our understanding of the function and complex regulation of these receptors has fueled the development of targeted therapeutic agents for human malignancies in the last 15 years. Here we review the biology of ErbB receptors, including their structure, signaling, regulation, and roles in development and disease, then briefly touch on their increasing roles as targets for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18259690      PMCID: PMC3060045          DOI: 10.1007/s00018-008-7440-8

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  195 in total

1.  The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling.

Authors:  E J Lowenstein; R J Daly; A G Batzer; W Li; B Margolis; R Lammers; A Ullrich; E Y Skolnik; D Bar-Sagi; J Schlessinger
Journal:  Cell       Date:  1992-08-07       Impact factor: 41.582

2.  Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal.

Authors:  S COHEN
Journal:  J Biol Chem       Date:  1962-05       Impact factor: 5.157

Review 3.  Negative regulation of receptor tyrosine kinases: unexpected links to c-Cbl and receptor ubiquitylation.

Authors:  Chanan Rubin; Gal Gur; Yosef Yarden
Journal:  Cell Res       Date:  2005-01       Impact factor: 25.617

Review 4.  The epidermal growth factor receptor pathway: a model for targeted therapy.

Authors:  Maurizio Scaltriti; José Baselga
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

5.  Expression and nuclear localization of ErbB3 in prostate cancer.

Authors:  Ismaël Hervé Koumakpayi; Jean-Simon Diallo; Cécile Le Page; Laurent Lessard; Martin Gleave; Louis R Bégin; Anne-Marie Mes-Masson; Fred Saad
Journal:  Clin Cancer Res       Date:  2006-05-01       Impact factor: 12.531

6.  Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.

Authors:  Marissa N Balak; Yixuan Gong; Gregory J Riely; Romel Somwar; Allan R Li; Maureen F Zakowski; Anne Chiang; Guangli Yang; Ouathek Ouerfelli; Mark G Kris; Marc Ladanyi; Vincent A Miller; William Pao
Journal:  Clin Cancer Res       Date:  2006-11-01       Impact factor: 12.531

Review 7.  Targeting the function of the HER2 oncogene in human cancer therapeutics.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

8.  HER2-mediated effects on EGFR endosomal sorting: analysis of biophysical mechanisms.

Authors:  Bart S Hendriks; H Steven Wiley; Douglas Lauffenburger
Journal:  Biophys J       Date:  2003-10       Impact factor: 4.033

9.  ErbB2 is required for muscle spindle and myoblast cell survival.

Authors:  Eran R Andrechek; William R Hardy; Adele A Girgis-Gabardo; Robert L S Perry; Richard Butler; Frank L Graham; Ronald C Kahn; Michael A Rudnicki; William J Muller
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

10.  KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

Authors:  Erminia Massarelli; Marileila Varella-Garcia; Ximing Tang; Ana C Xavier; Natalie C Ozburn; Diane D Liu; Benjamin N Bekele; Roy S Herbst; Ignacio I Wistuba
Journal:  Clin Cancer Res       Date:  2007-05-15       Impact factor: 12.531

View more
  200 in total

Review 1.  Dual targeting strategies with bispecific antibodies.

Authors:  Roland E Kontermann
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

2.  Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in head and neck cancer.

Authors:  Wei Yang; Quan Cai; Vivian W Y Lui; Patrick A Everley; Jayoung Kim; Neil Bhola; Kelly M Quesnelle; Bruce R Zetter; Hanno Steen; Michael R Freeman; Jennifer R Grandis
Journal:  J Proteome Res       Date:  2010-06-04       Impact factor: 4.466

Review 3.  Evaluating Trastuzumab in the treatment of HER2 positive breast cancer.

Authors:  Ryan Jaques; Sam Xu; Antonios Matsakas
Journal:  Histol Histopathol       Date:  2020-04-23       Impact factor: 2.303

4.  HER2 Signaling in Breast Cancer.

Authors:  Incheol Shin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Polyisoprenylated methylated protein methyl esterase: a putative biomarker and therapeutic target for pancreatic cancer.

Authors:  Byron J Aguilar; Augustine T Nkembo; Randolph Duverna; Rosemary A Poku; Felix Amissah; Seth Y Ablordeppey; Nazarius S Lamango
Journal:  Eur J Med Chem       Date:  2014-05-09       Impact factor: 6.514

6.  Beyond Autoantibodies: Biologic Roles of Human Autoreactive B Cells in Rheumatoid Arthritis Revealed by RNA-Sequencing.

Authors:  Ankit Mahendra; Xingyu Yang; Shaza Abnouf; Jay R T Adolacion; Daechan Park; Sanam Soomro; Jason Roszik; Cristian Coarfa; Gabrielle Romain; Keith Wanzeck; S Louis Bridges; Amita Aggarwal; Peng Qiu; Sandeep K Agarwal; Chandra Mohan; Navin Varadarajan
Journal:  Arthritis Rheumatol       Date:  2019-02-23       Impact factor: 10.995

7.  Neuregulin-4 is a survival factor for colon epithelial cells both in culture and in vivo.

Authors:  Jessica K Bernard; Sean P McCann; Vrinda Bhardwaj; Mary K Washington; Mark R Frey
Journal:  J Biol Chem       Date:  2012-10-02       Impact factor: 5.157

8.  Simulation of homology models for the extracellular domains (ECD) of ErbB3, ErbB4 and the ErbB2-ErbB3 complex in their active conformations.

Authors:  Juan Felipe Franco-Gonzalez; Javier Ramos; Victor L Cruz; Javier Martínez-Salazar
Journal:  J Mol Model       Date:  2012-10-23       Impact factor: 1.810

9.  Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3.

Authors:  Natalia Jura; Yibing Shan; Xiaoxian Cao; David E Shaw; John Kuriyan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-09       Impact factor: 11.205

10.  Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma.

Authors:  Guy A Weiss; Michael R Rossi; Nikhil I Khushalani; Ken Lo; John F Gibbs; Anubha Bharthuar; John K Cowell; Renuka Iyer
Journal:  J Gastrointest Oncol       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.